FTWA
OTLK icon

Fifth Third Wealth Advisors’s Outlook Therapeutics OTLK Stock Holding History

Fifth Third Wealth Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Buy
+10,000
New +$6.2K ﹤0.01% 990
2025
Q3 		– Sell
-10,000
Closed -$16K – 804
2025
Q2 		$16K Hold
10,000
– – ﹤0.01% 749
2025
Q1 		$12.2K Hold
10,000
– – ﹤0.01% 704
2024
Q4 		$18.9K Buy
+10,000
New +$41.1K ﹤0.01% 720

Other funds holding OTLK

CKAIS
Christensen King & Associates Investment Services Richland, Washington $252M AUM 20.51% 1-Year Est. Return
FCC
Flower City Capital Pittsford, New York $227M AUM 23.31% 1-Year Est. Return
OFS
Orrstown Financial Services Harrisburg, Pennsylvania $674M AUM 23.23% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return

Fifth Third Wealth Advisors's OTLK Position: Q2 2026 in Review

Fifth Third Wealth Advisors opened a new position in Outlook Therapeutics (OTLK) in Q2 2026: 10,000 shares worth $15.9K. The stake represents ﹤0.01% of the portfolio and ranks #990 among its holdings. This is a return to the name: Fifth Third Wealth Advisors previously reported a position in OTLK as recently as Q2 2025.

Fifth Third Wealth Advisors first reported a position in OTLK in Q4 2024 and has held it in 4 quarters since. The position peaked at $18.9K in Q4 2024. 6 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Fifth Third Wealth Advisors held 10,000 shares of Outlook Therapeutics worth $15.9K as of Q2 2026.
  • Outlook Therapeutics was a new Fifth Third Wealth Advisors position in Q2 2026.
  • Outlook Therapeutics made up ﹤0.01% of Fifth Third Wealth Advisors's portfolio in Q2 2026, its #990 holding.
  • Fifth Third Wealth Advisors first reported a position in Outlook Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Fifth Third Wealth Advisors's Outlook Therapeutics position peaked at $18.9K in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Fifth Third Wealth Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.